Application of medicament for regulating transcription factor EB to improve mitochondrial function in prevention and treatment of laying hen fatty liver
By measuring the TFEB gene expression and adding taurine to the feeding food of laying hens, the problem of fatty liver in laying hens was solved, the egg laying hens was significantly improved, and the egg laying rate and mitochondrial function were achieved, and the prevention and treatment effect was achieved.
Patent Information
- Application Number
- CN202411129499.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Fatty liver of laying hens is a common nutritional metabolic disease in laying hen farming, especially in the late stage of egg laying, which seriously affects egg laying rate and health. The existing technology has not yet effectively developed the application of the transcription factor TFEB in this.
By measuring the relative expression of TFEB genes and fatty acid oxidation genes in different egg laying cycles, it was found that TFEB was related to egg laying rate and fatty acid oxidation. Adding taurine to laying hens’ feed to intervene in the expression of TFEB, significantly increasing the Egg laying rate and mitochondrial function.
Regulating the expression of TFEB can effectively prevent and treat fatty liver in laying hens, improve health and egg laying performance in the later stage of egg laying, and have the advantages of simplicity of operation, low cost and significant effect.
Smart Images

Figure CN119033747A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of animal nutrition and healthy breeding, and relates to a method for preventing and treating fatty liver of laying hens and improving the egg production rate of laying hens by regulating the mRNA expression amount of transcription factor EB (TFEB) gene. Background Art
[0002] Fatty liver in laying hens, also known as fatty liver syndrome (FLS), is a common nutritional metabolic disease in laying hens. It mainly occurs in the peak and late egg-laying period of caged laying hens. The incidence rate in some flocks is over 30%, causing serious economic losses to the laying hen industry. With the implementation of the "extended breeding" program in my country's laying hen breeding industry, the breeding cycle is extended to 100 weeks of age, and the aging of the chicken population has increased, making FLS more frequent. The incidence rate in the late egg-laying period reaches over 50%, seriously affecting the egg production rate and the health of the chickens.
[0003] The liver is the main organ for material metabolism and plays an important role in the metabolism, storage, and transportation of endogenous and exogenous substances. As egg production increases and aging worsens, the liver's metabolic capacity declines, and the problem of fat deposition is particularly prominent. Preventing and controlling the occurrence and development of fatty liver syndrome in laying hens is one of the key issues to ensure the healthy development of the laying hen industry.
[0004] The formation of fatty liver is closely related to mitochondrial dysfunction. Mitochondrial dysfunction and its targeted treatment to alleviate FLS are hot and difficult issues in current research. In recent years, it has been found that the transcription factor TFEB has the function of regulating mitochondrial function, but its role in the occurrence and development of fatty liver in laying hens and its application in prevention and treatment strategies have not yet been developed. Summary of the invention
[0005] The purpose of the present invention is to provide a method for preventing and treating fatty liver in laying hens and improving the egg production rate of laying hens by regulating transcription factor EB to improve mitochondrial function.
[0006] In order to achieve the above purpose, the present invention first collects the liver of Roman pink laying hens in different egg-laying cycles, extracts RNA and reversely transcribes it into cDNA, and uses real-time PCR to determine the relative expression of TFEB gene and fatty acid oxidation genes CPT1A, ACOX1, and PPARα in different egg-laying processes, and performs correlation analysis on the relative expression of TFEB gene with egg-laying cycle, egg-laying rate, and fatty acid oxidation genes CPT1A, ACOX1, and PPARα. The results show that the expression of TFEB shows dynamic changes in the egg-laying process of laying hens, and there is a significant strong correlation between it and egg-laying rate, fatty acid oxidation, and fatty liver phenotype. It is speculated that the TFEB gene may be an important target for preventing or treating fatty liver in laying hens, and improving mitochondrial function by regulating the expression level of TFEB mRNA through nutritional regulatory substances is an effective and feasible method for preventing and treating fatty liver in laying hens and improving the egg-laying rate of laying hens.
[0007] Furthermore, nutritional regulatory substances were added to the feed of laying hens for intervention. The selected nutritional regulatory substance was taurine. The taurine content added to the feed was 0.05%, 0.1%, and 0.2%, respectively. The intervention started from the 46th week of Roman powder laying hens to 62 weeks. Then the liver was collected and the relative expression of TFEB gene and fatty acid oxidation genes CPT1A, ACOX1, and PPARα in laying hens after taurine intervention was determined. The results showed that the egg production rate of laying hens after intervention was improved, there was no obvious lipid droplet deposition in the liver, and the mRNA expression of TFEB, ACOX1, CPT1A, and PPARα genes in the liver of laying hens was significantly increased in the late egg-laying period. The above results show that taurine has a regulatory effect on transcription factor EB and mitochondrial function, can upregulate the mRNA expression of transcription factor EB, improve mitochondrial function, and then improve the liver lipid metabolism and fatty acid oxidation activity of laying hens in the late egg-laying period, alleviate the fatty liver phenotype, and improve the egg production rate of laying hens.
[0008] In conclusion, drugs that regulate transcription factor EB and improve mitochondrial function can be used to prevent and treat fatty liver in laying hens and increase the egg production rate of laying hens.
[0009] The beneficial effects of the present invention are:
[0010] The present invention proves the change rule of the synchronous decline of the mRNA expression of TFEB in the liver and the egg production rate, the fatty acid oxidation activity of the liver of the laying hens, and the liver mitochondrial activity of the laying hens from the peak of egg laying to the late egg laying period, that is, the gradual decline of the TFEB mRNA expression is accompanied by the gradual appearance of the fatty liver phenotype. By regulating the expression of TFEB, it is possible to effectively prevent and treat fatty liver in laying hens, and improve the egg laying performance and health level of laying hens in the late egg laying period. The method has the advantages of simple operation, low cost, and remarkable effect, which is of great significance for the laying hen breeding industry to improve economic benefits and animal welfare. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 :Oil red O stained sections of laying hens' livers at different egg-laying stages.
[0012] Figure 2 :Analysis on the relative expression of TFEB gene in liver of laying hens at different egg-laying stages and its correlation with laying age and egg production rate.
[0013] Figure 3 :Relative expression levels of fatty acid oxidation genes CPT1A, ACOX1, and PPARα in the liver of laying hens at different egg-laying stages and their correlation with the expression level of TFEB in the liver of laying hens at different egg-laying stages.
[0014] Figure 4 : Oil red O stained sections of chicken liver after taurine intervention.
[0015] Figure 5 : Taurine intervenes in the egg production rate of laying hens aged 3-8 weeks and 9-16 weeks.
[0016] Figure 6 : Relative expression levels of TFEB, fatty acid oxidation genes CPT1A, ACOX1, and PPARα in chicken liver after taurine intervention. DETAILED DESCRIPTION
[0017] The present invention is further illustrated below in conjunction with specific embodiments. The experimental methods in the following examples without specifying specific conditions are all conventional methods in the art. Unless otherwise defined, all professional and scientific terms used in the text have the same meaning as those familiar to professionals in the art. In addition, the materials, reagents, etc. used in the examples, unless otherwise specified, can all be obtained from commercial sources.
[0018] Example 1: Study on the dynamic changes of TFEB gene expression level in laying hen liver
[0019] 1. Materials and reagents
[0020] Table 1 Instruments
[0021]
[0022] Table 2 Reagents
[0023]
[0024] 2. Test methods
[0025] 2.1 Sample collection
[0026] The left and right livers of Roman pink laying hens at 20wk (beginning of laying), 36wk (peak of laying), 46wk (end of peak), 57wk (late laying), and 62wk (late laying) were collected and rinsed three times in sterilized PBS. Some samples were fixed in 4% paraformaldehyde fixative for 48h for making tissue sections; the other samples were quickly frozen in liquid nitrogen and stored on dry ice.
[0027] 2.2 Preparation of liver tissue sections
[0028] 1) Sectioning: Rewarm and dry the frozen sections, fix them in fixative for 15 min, wash with tap water, and air dry.
[0029] 2) Staining: Immerse the sections in oil red stain solution for 8-10 minutes in the dark, and then wash with distilled water.
[0030] 3) Differentiation: Differentiate slightly with 75% alcohol and wash with distilled water.
[0031] 4) Hematoxylin staining: Stain the sections with hematoxylin solution for 3-5 minutes, wash with tap water, differentiate, and turn blue.
[0032] 5) Sealing: Glycerin gelatin sealing.
[0033] 6) Microscopic examination: microscopic examination, image acquisition and analysis
[0034] 2.3 Total RNA extraction
[0035] 1) Remove part of the sample and put it into a pre-cleaned and sterilized mortar, add liquid nitrogen and grind it into powder.
[0036] 2) Take about 100 mg of the ground sample into a 1.5 mL enzyme-free EP tube, add 1 mL of Trizol reagent for lysis, let stand at room temperature for 10 min, and centrifuge at 4°C 12000 r / min for 10 min.
[0037] 3) Take the supernatant and place it in a new 1.5 mL enzyme-free EP tube, add 200 μL of chloroform, shake vigorously for 1 min, let stand on ice for 10 min, and centrifuge at 4°C, 12,000 rpm for 10 min.
[0038] 4) Transfer the upper aqueous phase to a new 1.5 mL enzyme-free EP tube, add an equal amount of pre-cooled isopropanol, mix by inversion for 30 seconds, place on ice for 10 minutes, and centrifuge at 4°C, 12,000 rpm for 10 minutes.
[0039] 5) Discard the supernatant, add 1 mL of pre-cooled 75% ethanol, flick the precipitate, and centrifuge at 4°C, 12,000 rpm, for 5 min. Repeat this step twice.
[0040] 6) Discard the supernatant, let it dry naturally, and add an appropriate amount of DEPC water to dissolve the precipitate.
[0041] 7) Take 1 μL of RNA sample and measure the RNA concentration using an ultra-micro spectrophotometer.
[0042] 2.4 Reverse transcription
[0043]
[0044] 2.5 Real-time PCR
[0045] cDNA was subjected to Real-time PCR to determine the relative expression levels of TFEB gene and fatty acid oxidation genes CPT1A, ACOX1, and PPARα in laying hens at different egg-laying stages. β-actin was used as the internal reference gene and the relative expression levels were calculated according to the 2-△△CT algorithm.
[0046]
[0047] TFEB gene, fatty acid oxidation gene: CPT1A, ACOX1, PPARα and reference gene are as follows:
[0048] Table 3 Fluorescence quantitative PCR primer sequences
[0049]
[0050] 2.6 Data Analysis
[0051] The relative expression level of TFEB gene was correlated with egg-laying cycle, egg-laying rate and fatty acid oxidation genes CPT1A, ACOX1 and PPARα.
[0052] All data were analyzed using SPSS24.0 software and plotted using GraphPad Prism 9.4.1 software. The data were expressed as mean±SD, and p<0.05 was considered statistically significant.
[0053] 3. Test results
[0054] like Figure 1 As shown, the liver was stained with Oil Red O, and it was found that the degree of lipid droplet accumulation in the liver increased with the progress of egg laying, and was particularly serious in the late egg laying period.
[0055] like Figure 2 As shown in the data, during the egg-laying peak to late egg-laying period, the expression level of TFEB mRNA in the liver decreased synchronously with the egg-laying rate, showing a high positive correlation. The expression level of TFEB mRNA in 57wk and 62wk laying hens was significantly lower than that in 36wk laying hens (p<0.05).
[0056] like Figure 3As shown in the figure, compared with 20wk, the mRNA expression levels of fatty acid oxidation-related genes CPT1A and ACOX1 in the liver of laying hens at 36wk, 46wk, and 57wk were significantly increased (p<0.05), and the mRNA expression levels of CPT1A and ACOX1 in the liver of laying hens at 62wk were significantly lower than those in the 36wk period (p<0.05). The expression level of PPARα mRNA in the liver of laying hens at 57wk was significantly higher than that in other periods (p<0.05), and the expression level of PPARα mRNA in the liver of laying hens at 62wk was significantly reduced (p<0.05). The correlation analysis of TFEB mRNA expression level with the expression levels of fatty acid oxidation genes CPT1A, ACOX1, and PPARα mRNA found that TFEB expression level had a strong correlation with CPT1A and ACOX1 expression levels, and a moderate correlation with PPARα expression level.
[0057] The expression of TFEB changes dynamically during the egg-laying process of laying hens, and there is a significant strong correlation between it and egg production rate, fatty acid oxidation and fatty liver phenotype. During the peak egg-laying period, high expression of TFEB may help maintain mitochondrial fatty acid oxidation capacity, while its decrease in the late egg-laying period may be related to the development of fatty liver. Regulating the expression of TFEB through nutrients may provide a new strategy for the prevention and treatment of fatty liver in laying hens, which helps to improve the health and egg-laying performance of laying hens.
[0058] Example 2: Effect of regulating the expression level of TFEB gene in laying hen liver on alleviating fatty liver
[0059] 1. Test methods
[0060] The taurine content added to the diet was 0.05%, 0.1%, and 0.2%, respectively. Taurine intervention started at 46wk and continued until 62wk. The left and right livers of Roman pink laying hens at 62wk, 62wk+0.05% Tau, 62wk+0.1% Tau, and 62wk+0.2% Tau were collected and rinsed three times in sterilized PBS. Some samples were fixed in 4% paraformaldehyde fixative for 48h for tissue sectioning; the other samples were quickly frozen in liquid nitrogen and stored on dry ice.
[0061] The sample processing and detection are the same as in Example 1.
[0062] 2. Test results
[0063] like Figure 4 As shown in the data, after taurine intervention, the egg production rate of laying hens was increased in the 3rd to 8th week and the 9th to 16th week of intervention.
[0064] like Figure 5As shown, by Oil Red O staining of liver sections of laying hens after taurine intervention, there was no obvious orange-red lipid droplet deposition in the liver of laying hens in the treatment group at 62 weeks of egg production, compared with the control group at 62 weeks of egg production.
[0065] like Figure 6 As shown in the results, after taurine intervention, it was found that the addition of 0.2% taurine in the diet significantly increased the expression of TFEB mRNA in the liver of laying hens in the late egg-laying period (p<0.05). The addition of 0.2% taurine in the diet significantly increased the expression of ACOX1 mRNA, a fatty acid oxidation gene, in the liver of laying hens in the late egg-laying period (p<0.05); the addition of 0.05%, 0.1%, and 0.2% taurine in the diet significantly increased the expression of CPT1A mRNA in the liver of laying hens in the late egg-laying period (p<0.05); the addition of 0.1% and 0.2% taurine in the diet significantly increased the expression of PPARα mRNA in the liver of laying hens in the late egg-laying period (p<0.05).
[0066] As a nutritional regulatory substance, taurine significantly upregulates the expression level of TFEB in the liver of laying hens, thereby activating mitochondrial fatty acid oxidation activity, effectively alleviating the fatty liver phenotype of laying hens in the late laying period, and improving the egg production rate of laying hens in the late laying period.
[0067] In summary, the present invention reveals the key role of the TFEB gene in the egg-laying process of laying hens, as well as the potential effect of regulating TFEB expression through taurine intervention on the prevention and treatment of fatty liver in laying hens. Studies have shown that changes in the expression levels of TFEB and its regulated fatty acid oxidation genes during egg-laying are closely related to liver lipid accumulation. The addition of taurine can significantly improve the liver lipid metabolism of laying hens in the late egg-laying period, increase the expression levels of related genes, and thus reduce the risk of fatty liver. These findings provide new strategies for the prevention and treatment of fatty liver in laying hens, and emphasize the potential of regulating gene expression through nutritional intervention in improving poultry health and production performance.
Claims
1. Application of drugs that regulate transcription factor EB to improve mitochondrial function in preventing and treating fatty liver in laying hens.
2. The application of drugs that regulate transcription factor EB to improve mitochondrial function in increasing the egg production rate of laying hens.
3. The use according to claim 1 or 2, characterized in that: The agent that regulates transcription factor EB and improves mitochondrial function includes taurine.
4. A method for preventing and treating fatty liver in laying hens or improving egg production rate in laying hens, characterized in that: Adding an effective dose of taurine to the feed of laying hens in the late egg-laying period can upregulate the mRNA expression of transcription factor EB through taurine, improve mitochondrial function, and thus improve the liver lipid metabolism and fatty acid oxidation activity of laying hens in the late egg-laying period, alleviate the fatty liver phenotype, and increase the egg production rate of laying hens.
Citation Information
Patent Citations
Premix for preventing fatty liver syndrome of laying hens
CN113397061A
Application of taurine in preparation of medicine for preventing and treating animal fatty liver
CN117959271A
Composition containing litchi seed extract for preventing or treating fatty liver or obesity
WO2011090271A2
